Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)

US9365558B2 - Dihydropyridinone MGAT2 inhibitors - Google Patents

Inhibition of MGAT2 modulates fat‐induced gut peptide release and

TP-020 (MGAT2-IN-1), MGAT2 Inhibitor

Beyond triglyceride synthesis: the dynamic functional roles of

Full article: Patent landscape for discovery of promising

Medicina, Free Full-Text

Metabolomics combined with network pharmacology exploration

The monoacylglycerol acyltransferase pathway contributes to

Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the

Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the

Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the

The monoacylglycerol acyltransferase pathway contributes to

Cancers, Free Full-Text

Ablation of the deubiquitinase USP15 ameliorates nonalcoholic

Targeting diacylglycerol acyltransferase 2 for the treatment of